Preclinical and translational ADC development at World ADC London 2027

Mar 8–11, 2027 London, UK ~700 attendees Website

9 organizations at World ADC London 2027 present work in preclinical & translational: 4 technology and service providers, 3 drug developers and 2 academic, government and non-profit bodies. Between them they bring 7 presentations to the program. Most represented: University of Michigan, Bionavigen and Cancer Research Center of Lyon. As of Oct 8, 2026.

All 75 organizations at World ADC London 2027 →

Showing 1–9 of 9 organizations

Organization	World ADC London 2027 Attendance
University of Michigan Ann Arbor, MI
umich.edu Academic & healthcare Public research university in Ann Arbor, Michigan.	Talk Antibody Design for Effective ADCs: The Multiple Impacts of Fc Engineering Pre-conference: 5th Novel Conjugates Day Panel Tue Mar 9 5:00pm Trailblazing Next Generation of ADC’s from XDC’s to Dual Payload Innovation to Develop Safer & More Efficacious ADC Drugs from Concept to Clinic Validation Plenary · with Queen's University Belfast, Callio Therapeutics, Iksuda Therapeutics ADC discoveryClinical development Workshop Thu Mar 11 9:00am Accelerating ADC Model Simulation with the Power of Artificial Intelligence & Machine Learning Post-conference workshop for Pre-Clinical & Translation
Bionavigen
bionavigen.com Consulting & other services Biopharmaceutical consultancy advising on drug discovery, preclinical and clinical development, and in-licensing of early-stage assets.	Talk Opportunities for Improving the Translational Safety of ADCs From NHPs to Humans Pre-conference: 4th Toxicity Day Clinical development
Cancer Research Center of Lyon Lyon, France
crcl.fr Academic & healthcare Cancer research center in Lyon run jointly by Inserm, CNRS, the University of Lyon and the Centre Léon Bérard.	Workshop Thu Mar 11 1:00pm Selecting & Validating Models for ADC Efficacy & Safety Post-conference workshop for Pre-Clinical & Translational
LigaChem Biosciences Daejeon, South Korea
ligachembio.com Biotech Korean biotech developing ADCs on its site-specific conjugation platform, including a CLDN18.2-targeted candidate, and licensing the technology to partners.	Talk Advancing In Vitro Model Selection for Bone Marrow, Liver & Lung to Test Pre Clinical Activity & Toxicity Preclinical & Translational
Pfizer New York, NY
pfizer.com Large pharma Global pharmaceutical company whose oncology portfolio includes ADCs gained with Seagen, such as PADCEV.	Talk Treating Cancer From the Outside In: The Preclinical & Early Clinical Development of PF-08052667 for Non Muscle Invasive Bladder Cancer Preclinical & Translational Clinical development
Biocytogen Beijing, China	◇Exhibition Partner
biocytogen.com BiotechExhibition Partner Discovers fully human antibodies on its mouse platforms for partners, and supplies humanized animal models and pharmacology services for antibody and ADC programs.	Sponsor In the meeting’s sponsor directory, with no session on the public program
HUB Organoids Utrecht, Netherlands	◇Program Partner
huborganoids.nl Reagents, materials & modelsProgram Partner Dutch organoid company providing patient-derived organoid models and testing to assess drug efficacy and toxicity.	Sponsor In the meeting’s sponsor directory, with no session on the public program
LIDE Biotech Shanghai, China	◇Program Partner
lidebiotech.com CDMOs & CROsProgram Partner Preclinical oncology CRO offering in vitro assays, patient-derived and cell-line xenograft mouse models, and rapid in vivo tests for evaluating ADCs.	Sponsor In the meeting’s sponsor directory, with no session on the public program
Pharmaron Beijing, China	◇Program Partner
pharmaron.com CDMOs & CROsProgram Partner Integrated drug R&D services company offering chemistry, biology, preclinical, clinical and manufacturing services, including ADC programs.	Sponsor In the meeting’s sponsor directory, with no session on the public program